Addressing Scalability Challenges in Cell Therapy Manufacturing

Addressing Scalability Challenges in Cell Therapy Manufacturing

As cell and gene therapy production continues to move towards commercialisation, it faces new challenges relating to the scalability of manufacturing processes. Both autologous and allogeneic therapies hold their own unique obstacles relating to production and treatment; and the promise of personalised medicines is not without hindrances related to both cost and availability.

We interviewed Andrew Finnerty, General Manager, CCMI Ireland at NUI Galway to discuss this topic in more detail and build a better understanding of how the rapid expansion of this market has brought about new challenges relating to manufacturing scalability , and what will this mean for the future of personalised cell and gene therapies. 



Please note: That all fields marked with an asterisk (*) are required.